

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Qianhai Health Holdings Limited**

**前海健康控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

(Stock Code: 911)

## **SUPPLEMENTAL ANNOUNCEMENT TO ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024**

Reference is made to (i) supplemental announcement (the “**2023 Announcement**”) of Qianhai Health Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to the annual results announcement and annual report for the year ended 31 December 2022 (“**FY2022**”) dated 7 June 2023; (ii) the annual results announcement (the “**2024 Annual Results Announcement**”) of the Company for the year ended 31 December 2024 (“**FY2024**”); and (iii) the annual report (the “**2024 Annual Report**”) of the Company for FY2024. Capitalised terms used herein shall have the same meanings as those defined in the 2023 Announcement, the 2024 Annual Results Announcement and the 2024 Annual Report unless the context requires otherwise.

The Company would like to supplement the 2024 Annual Results Announcement and the 2024 Annual Report with the following information in relation to the provision for onerous contracts.

As disclosed in the 2024 Annual Results Announcement and the 2024 Annual Report, the Group recognised a provision for onerous contracts of approximately HK\$60.4 million for FY2024: (a) as to approximately HK\$42.0 million in relation to the Supplier Products, which were procured by the Group during FY2022; and (b) as to approximately HK\$18.4 million in relation to electronic component products procured by the Group during FY2024 (the “**2024 Products**”).

## **The Supplier Products**

As disclosed in the 2023 Announcement, provision for onerous contracts was made with respect to the Supplier Products for FY2022. As the market price of the Supplier Products were still below their purchase costs (after provision) and overdue penalties, further provisions were to be made in respect of the Supplier Products for FY2024. As the Group disposed of the then subsidiary of the Company, which contracted for the purchase of the Supplier Products, to an independent third party in early December 2024, a provision for onerous contracts of approximately HK\$42.0 million was recognised by the Company with respect to the Supplier Products as at 30 November 2024, being the month end immediately prior the disposal of the Then Subsidiary.

## **The 2024 Products**

In accordance with the internal control policy of the Group, the Group would monitor the market price of the relevant products every week, and may not make any further procurement in the event that the market price is lower than the purchase price.

However, due to volatile nature of the electronics components market, prices of electronics component products can experience enormous fluctuations. The prices of certain electronics component products procured by the Group during FY2024 experienced sharp downturns during the year.

As the market prices of the 2024 Products were lower than their respective prices when the Group entered into contracts for their purchase during FY2024, a provision for onerous contracts of approximately HK\$18.4 million was made with respect to such electronics component products.

The above additional information does not affect other information contained in the 2024 Annual Results Announcement and the 2024 Annual Report. All other information in the 2024 Annual Results Announcement and the 2024 Annual Report remains unchanged.

By order of the Board  
**Qianhai Health Holdings Limited**  
**Huang Zhiqun**  
*Chairman*

Hong Kong, 19 December 2025

*As at the date of this announcement, the non-executive Directors are Mr. Huang Zhiqun, Chen Kaiben and Mr. Chen Qi; the executive Directors are Mr. Tang Yu Yuan and Mr. Yuen Chee Lap Carl; and the independent non-executive Directors are Mr. Li Wei, Mr. Leung Chun Tung and Ms. Wu Hung Yu.*